There is currently a CCR9 antagonist that shows promise in clinical trials for Crohn's disease [49,50], in fact this is one of the few clinical trials targeting chemokine receptors that show hope in the treatment of inflammatory diseases. The gene discussed is CCR9; the disease is Crohn disease.